Citius Pharmaceuticals Valuation
| CTXR Stock | USD 1.47 0.00 0.00% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Citius Pharmaceuticals shows a prevailing Real Value of $2.55 per share. The current price of the firm is $1.47. Our model approximates the value of Citius Pharmaceuticals from analyzing the firm fundamentals such as Return On Equity of -0.61, current valuation of 17 M, and Shares Owned By Insiders of 4.41 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Citius Pharmaceuticals' valuation include:
Undervalued
Today
Please note that Citius Pharmaceuticals' price fluctuation is extremely dangerous at this time. Calculation of the real value of Citius Pharmaceuticals is based on 3 months time horizon. Increasing Citius Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Citius stock is determined by what a typical buyer is willing to pay for full or partial control of Citius Pharmaceuticals. Since Citius Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Citius Stock. However, Citius Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.47 | Real 2.55 | Target 6.0 | Hype 1.55 | Naive 1.01 |
The intrinsic value of Citius Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Citius Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Citius Pharmaceuticals helps investors to forecast how Citius stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Citius Pharmaceuticals more accurately as focusing exclusively on Citius Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Citius Pharmaceuticals' intrinsic value based on its ongoing forecasts of Citius Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Citius Pharmaceuticals' closest peers.
Citius Pharmaceuticals Cash |
|
Citius Valuation Trend
Citius Pharmaceuticals' real value is important for investors to make better decisions and a more accurate overall view of Citius Pharmaceuticals' financial worth over time. Using both Citius Pharmaceuticals' enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Citius Pharmaceuticals Total Value Analysis
Citius Pharmaceuticals is currently anticipated to have valuation of 17 M with market capitalization of 16.09 M, debt of 262.87 K, and cash on hands of 48.04 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Citius Pharmaceuticals fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
17 M | 16.09 M | 262.87 K | 48.04 M |
Citius Pharmaceuticals Asset Utilization
One of the ways to look at asset utilization of Citius is to check how much profit was generated for every dollar of assets it reports. Citius Pharmaceuticals shows a negative utilization of assets of -0.25 percent, losing $0.002532 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Citius Pharmaceuticals shows how discouraging it operates for each dollar spent on its assets.Citius Pharmaceuticals Ownership Allocation
The market capitalization of Citius Pharmaceuticals is $16.09 Million. Citius Pharmaceuticals shows 4.41 percent of its outstanding shares held by insiders and 5.68 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Citius Pharmaceuticals Profitability Analysis
Net Loss for the year was (39.43 M) with profit before overhead, payroll, taxes, and interest of 0.About Citius Pharmaceuticals Valuation
The stock valuation mechanism determines Citius Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Citius Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Citius Pharmaceuticals. We calculate exposure to Citius Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Citius Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -174.9 K | -166.1 K |
Citius Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Citius Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 11.6 M | |
| Forward Price Earnings | 9.1324 |
Citius Pharmaceuticals Current Valuation Indicators
Citius Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Citius Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Citius Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Citius Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Citius Pharmaceuticals' worth.Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.